Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy
BackgroundImmune-mediated necrotizing myopathy (IMNM) is a rare autoimmune disease. Efgartigimod is a human IgG antibody Fc fragment, can enhance the degradation of IgG and thus may be a promising therapeutic agent for IMNM.MethodsAll three patients exhibited proximal muscle weakness and markedly in...
Saved in:
| Main Authors: | Qiqi Peng, Xiaoping Yao, Sheng Chen, Xiaofeng Li, Feifei Lin, Zhangyu Zou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1560483/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis
by: Jia-Jun Cheng, et al.
Published: (2025-08-01) -
The FcRn from gene to protein and function: comparison between species
by: Luz Belinda Ortiz-Alegría, et al.
Published: (2025-08-01) -
Advanced human FcRn knock-in mice for pharmacokinetic profiling of therapeutic antibodies
by: SuBin Lee, et al.
Published: (2025-07-01) -
Long‐Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection
by: Geetha Jyothi Vaskuri, et al.
Published: (2025-08-01) -
Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis
by: Hui‐Ning Li, et al.
Published: (2025-08-01)